Chase Therapeutics Corporation
Latest round
- Series B
Last raised
- Oct 2021
Total raised
- $20M
Investors
- 4
About Chase Therapeutics Corporation
Chase Therapeutics Corporation, founded in 2017 and headquartered in Washington, US, specializes in the development of treatments for neuropsychiatric diseases. The company has undergone strategic pivots to enhance its focus on these areas.Chase Therapeutics is engaged in the development of innovative pharmaceutical products aimed at addressing neuropsychiatric diseases, particularly focusing on Parkinson’s disease and major depressive disorder. The company's lead products, CTC-413 and CTC-501, provide symptomatic relief and neuroprotection for patients suffering from these conditions and are currently progressing through Phase 2 clinical evaluations.Chase Therapeutics generates revenue through partnerships with healthcare institutions and clinical trial collaborations, which are essential to its drug development strategy. The company engages in agreements with clinical research organizations, hospitals, and specialty pharmacies, facilitating distribution of its products upon market release. The company is also focused on completing the development and validation of a diagnostic product for Parkinson’s Disease. Future expansions into new markets are anticipated, particularly in Europe, where there is a significant demand for advanced neuropsychiatric treatments.
Who invested in Chase Therapeutics Corporation
4 investors across 1 round
See all investors in Chase Therapeutics Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Oct 20, 2021
Amount
$20M
Investors
Questions about Chase Therapeutics Corporation
Who invested in Chase Therapeutics Corporation?
Chase Therapeutics Corporation has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Chase Therapeutics Corporation raised?
Chase Therapeutics Corporation has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Chase Therapeutics Corporation last raise money?
Chase Therapeutics Corporation's most recent round on record is a Series B, in Oct 2021.
What does Chase Therapeutics Corporation do?
Chase Therapeutics Corporation, founded in 2017 and headquartered in Washington, US, specializes in the development of treatments for neuropsychiatric diseases.
Where is Chase Therapeutics Corporation headquartered?
Chase Therapeutics Corporation is headquartered in Washington, US.
Which VCs invest in companies like Chase Therapeutics Corporation?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Chase Therapeutics Corporation's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Chase Therapeutics Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.